Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Neumora Therapeutics, Inc. (NMRA) ownership disclosure lists Paul L Berns, the reporting person, as beneficially owning 10,201,627 shares, or 5.4%, as of September 30, 2026. The amount comprises 7,708,851 common shares and options to purchase 2,492,776 shares that were vested or would vest within 60 days. The stated percentage is based on 187,895,912 common shares outstanding as of August 10, 2026; the disclosure says the options were included in that count.
Key Figures
Beneficially owned shares:10,201,627 sharesClass ownership:5.4%Common shares:7,708,851 shares+2 more
5 metrics
Beneficially owned shares10,201,627 sharesPaul L Berns as of September 30, 2026
Class ownership5.4%Reported percentage of the class
Common shares7,708,851 sharesRecord shares beneficially owned as of September 30, 2026
Options to purchase common shares2,492,776 sharesOptions vested or to vest within 60 days as of September 30, 2026
Common shares outstanding187,895,912 sharesAs of August 10, 2026; the disclosure says the Berns Options were included
Key Terms
beneficial owner, Sole Voting Power, Sole Dispositive Power
3 terms
beneficial ownerregulatory
"Berns is the beneficial owner of 7,708,851 shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Sole Voting Powerregulatory
"Sole Voting Power 10,201,627.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Powerregulatory
"Sole Dispositive Power 10,201,627.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Neumora Therapeutics (NMRA) shares did Paul L Berns beneficially own?
Paul L Berns reported beneficial ownership of 10,201,627 shares, or 5.4%, as of September 30, 2026. The amount includes common shares and options to purchase common shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Neumora Therapeutics, Inc.
(Name of Issuer)
Common Stock par value $0.0001 per share
(Title of Class of Securities)
640979100
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
640979100
1
Names of Reporting Persons
Paul L Berns
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
10,201,627.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
10,201,627.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,201,627.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Neumora Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
260 Arsenal Place, Suite 1, Watertown, MA 02472
Item 2.
(a)
Name of person filing:
Paul L Berns ("Berns") an individual and referred to as the "Reporting Person".
(b)
Address or principal business office or, if none, residence:
260 Arsenal Place, Suite 1, Watertown, MA 02472
(c)
Citizenship:
The Reporting Person is a US citizen.
(d)
Title of class of securities:
Common Stock par value $0.0001 per share
(e)
CUSIP No.:
640979100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Berns is the beneficial owner of 7,708,851 shares of Common Stock (the "Record Shares") as of September 30, 2026. In addition, as of September 30, 2026, Berns is a holder of options to purchase 2,492,776 shares of Common Stock that are currently vested or will vest within sixty days (the "Berns Options").
(b)
Percent of class:
See line 11 of the cover sheet. The percentages set forth on the cover sheet is based upon 187,895,912 shares of Common Stock outstanding as of August 10, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on August 14, 2026. The Berns Options were included in the number of shares of Common Stock outstanding.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See line 5 of the cover sheet.
(ii) Shared power to vote or to direct the vote:
See line 6 of the cover sheet.
(iii) Sole power to dispose or to direct the disposition of:
See line 7 of the cover sheet.
(iv) Shared power to dispose or to direct the disposition of:
See line 8 of the cover sheet.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.